Takeda and Noile-Immune Biotech collaborate to advance next generation CAR-T therapy effective for solid tumors.
Maverick Therapeutics Inc. and Takeda will collaborate to develop a biologics platform for T-cell immunotherapy over the next five years.
Takeda Pharmaceuticals and PvP Biologics have signed an agreement to develop therapeutics targeting celiac disease.
Derek Wallace, global dengue program medical director of Takeda Pharmaceutical Company, on the company's plans for dengue and Zika vaccines.
The collaboration will focus on discovery, development and commercialization of Humabodies®, a novel class of protein therapeutics.
The US$19.8 million initial funding will cover the development of a Zika vaccine through to a Phase I clinical trial.
A significantly greater proportion of patients in the treatment group versus the placebo group achieved combined remission at week 24.
The partnership will develop Altos’s proprietary compound ATC-1906 to address the symptoms of nausea and vomiting in gastroparesis patients.
With this funding, Takeda will develop, license and supply at least 50 million doses of a polio vaccine per year to more than 70 developing countries.